<DOC>
	<DOCNO>NCT01494285</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , 3-arm , parallel-group , ambulatory safety efficacy study ARK-E021 topical foam 5 % 10 % subject mild moderate acne vulgaris .</brief_summary>
	<brief_title>Clinical Study Evaluate Tolerability Safety ARK-E021 Foam Monitor Clinical Effect Acne Vulgaris Patients</brief_title>
	<detailed_description>This phase I/II prospective , multicenter , randomize , double blind , placebo control , parallel group , dose range find clinical study evaluate safety , tolerability preliminary efficacy ARK-E021 foam treatment acne vulgaris . It anticipate study conduct list Medical Centers well out-patient clinic community . Approximately 144 male female subject mild moderate facial acne vulgaris enrol study . Following satisfaction entry criterion screen procedure , subject randomize either 5 % 10 % topical foam ( ARK-E021 ) placebo foam . Subjects apply study medication daily face bedtime 12 week follow post-treatment follow visit 4 week end treatment . The first dose apply presence study investigator assignee . Subsequent application make patient . Safety monitor throughout study duration . Efficacy assess facial lesion count investigator global evaluation acne severity baseline week 3 , 6 , 9 , 12 16 .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Main Patient male female age 12 40 . A clinical diagnosis acne vulgaris facial involvement . Minimum 15 inflammatory lesion face ( papule and/ pustule ) 40 . Existence noninflammatory lesion face ( open and/or closed comedo ) . A score â‰¥2 ( moderate ) investigator 's global assessment scale . Use non oral contraceptive female childbearing potential study . No known medical condition , Investigator 's opinion could interfere study participation . Patient willing able comply requirement study protocol . Patient willing able give write informed consent prior participation study . Main Acne conglobata , acne fulminans , secondary acne ( chloracne , drug induce acne ) , severe acne require systemic treatment . One active nodule/cyst acne face ( inactive lesion allow ) . Excessive facial hair ( e.g . beard , sideburn , moustache , etc . ) would interfere diagnosis assessment acne vulgaris . Participation another investigational drug trial within 30 day prior study entry . Concomitant medication : Use systemic steroid , systemic antibiotic , systemic treatment acne vulgaris , systemic antiinflammatory agent within 4 week prior baseline study . Use topical steroid , topical antibiotic , topical treatment acne vulgaris , topical antiinflammatory agent within 2 week prior baseline study . Treatment acne isotretinoin isotretinoin derivative within 12 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Acne Vulgaris</keyword>
	<keyword>Topical</keyword>
	<keyword>Foam</keyword>
</DOC>